AbbVie Inc. has successfully navigated the revenue loss from Humira with its new drugs Skyrizi and Rinvoq, which now exceed Humira's peak sales. Despite trading at a forward P/E below the pharma average and projecting double-digit immunology growth, the author rates ABBV a hold due to high leverage and pipeline execution risk. While it offers a strong dividend and defensive qualities, the current valuation is considered fair rather than a bargain.

Robert Shearer, a Director at Church & Dwight Co Inc (CHD), sold 8,600 shares of the company on June 11, 2026, reducing his holding to 860 shares. This transaction follows a pattern of 7 insider sells versus 3 insider buys for the company over the past year. Church & Dwight Co Inc's stock is currently trading at $97.97 and is considered fairly valued with a price-to-GF-Value ratio of 0.92, despite its P/E ratio being higher than the industry median.

Teradyne Robotics will showcase its industrial automation applications, featuring physical AI, at Automate 2026 in Chicago. The demonstrations will include robotic systems from Universal Robots and Mobile Industrial Robots, highlighting tasks in manufacturing and other variable environments. A key focus will be PolyScope X, Universal Robots’ updated software platform, and various AI-driven applications for electronics manufacturing and AI data center infrastructure, along with partner demonstrations of adaptive automation.

AbbVie (NYSE:ABBV) announced new nine-year data from its Phase 3 CLL14 trial at the EHA 2026 Congress, reinforcing the long-term efficacy and safety of its venetoclax-based combination therapy for chronic lymphocytic leukemia (CLL). The data showed a significant improvement in progression-free survival and a median time to next treatment of 7.6 years. Benzinga Edge's scorecard for ABBV highlights strong quality metrics but notes a premium valuation, with moderate growth and momentum scores suggesting a need for additional catalysts.

UBS has reiterated a Neutral rating on Clorox (NYSE:CLX) stock with a $96.00 price target, acknowledging near-term challenges like weaker category growth, slower progress in litter, and cost inflation. Despite these headwinds, the stock is considered slightly undervalued with a 5.05% dividend yield, but UBS advises investors to stay on the sidelines due to pressure on top-line growth and limited earnings visibility. Recent news also includes CEO Linda Rendle's departure for health reasons and a $1.5 billion debt offering, alongside revised price targets from other analyst firms reflecting ongoing challenges.

A federal judge in California has ruled in favor of Apple Inc., granting summary judgment in a case where workers sought to include restricted stock units in their overtime pay calculations. The court determined that the Fair Labor Standards Act's "gift" and "equity" exceptions allowed Apple to exclude these stock values from regular rate of pay calculations. This decision addresses a "novel question" regarding federal wage law.

New analysis from the CATALYST clinical trial indicates that Korlym (mifepristone) can help lower blood sugar and promote weight loss in diabetes patients with high cortisol levels who are also on GLP-1 targeting medications. Corcept Therapeutics presented these findings, which suggest that modulating cortisol can improve metabolic parameters even for those with poorly controlled type 2 diabetes despite powerful GLP-1 therapies. Korlym works by blocking cortisol receptors and has shown better results than placebo in reducing HbA1c, body weight, waist circumference, and BMI.

S&P Global (SPGI) is highlighted as a strong wide-moat financial stock to consider. The article emphasizes its multiple competitive advantages, including its dominant credit ratings and indexing businesses, along with its Market Intelligence segment. Despite a recent stock price dip, its current valuation makes it an attractive buying opportunity for investors.

Realty Income (O) presents an attractive investment for retirees with a 5.3% yield and a strong track record of 670 consecutive monthly dividends. The company has demonstrated dividend safety through various economic challenges, supported by a healthy 73% AFFO payout ratio and projected 9% total operational return for 2026. Despite elevated leverage, the shifting interest rate environment and impressive occupancy rates suggest a dependable monthly payout for income-focused investors.

This article argues that investors should consider Pfizer (NYSE:PFE) over Eli Lilly (NYSE:LLY), especially given current market volatility. While Eli Lilly's stock is soaring due to GLP-1 drugs, it presents a concentrated risk with two primary revenue drivers and a high valuation. In contrast, Pfizer offers a diversified portfolio, recent patent cliff resolution, ongoing restructuring, active insider buying, and a strong 6.6% dividend yield.